PUBLIC COMPANY
saveRISING
USupdated 4mo ago
community read0 votes
pipeline
0
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(0)
no pipeline products on record
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →🐶 Hiring Signal
News
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 1d ago
- Novartis’ board faces investor scrutiny after M&A misfires and R&D flopsBack-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.biospace · 2d ago
- Lonza to build new US factory; Samsung Bio signs $262M contractPlus, news about Boston Scientific. Lonza’s new factory in the US: Lonza is expanding its US capacity with a new commercial spray-drying facility in Bend, OR. The new build is ...endpoints · 2d ago
- Mass. governor makes pre-election pitch to biotechs amid warning early-stage start-ups are 'dying'It may have seemed like an ordinary Wednesday afternoon at MassBio’s headquarters in Technology Square, but the black SUV parked outside was a telltale sign that the Cambridge, Massachusetts-based…fiercebiotech · 3d ago
- Webinar: The Massive Scale of GLP-1s: Evolving Health, Healthcare and MarketsWatch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and lea…biospace · 3d ago
- 2026 IPO stock tracker: How newly public biotechs are performingBioSpace is launching an IPO dashboard to help the industry keep tabs on U.S. biotechs that have taken the public plunge in 2026.biospace · 3d ago
- Tyra rolls toward pivotal bladder cancer study even as midphase data deflates stockTyra Biosciences has reported initial phase 2 data on dabogratinib in bladder cancer, putting the biotech on course to start a registrational study next year. But the biotech’s stock fell in premar…fiercebiotech · 4d ago
- Beyond China: Five other overseas destinations for biopharma dollarsAs geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for biotech investments.biospace · 4d ago
- An administrative gap delays access to new pancreatic cancer treatmentA new wave of illegal fruity vapes, more and more kids on GLP-1s, and other health news from Morning Roundsstat · 4d ago
- Pharvaris' latest phase 3 win builds case for HAE drug with FDA verdict pendingPharvaris’ deucrictibant has tasted success in a second phase 3 study, strengthening the case for the therapy to treat hereditary angioedema patients as the Swiss biotech awaits an FDA approval dec…fiercebiotech · 4d ago
comments(0)
5-min edit window · permanent after that